Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72

Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180

October 29, 2015 10:46 AM EDT

UBS reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target to $180.00 (from $168.00), following the company's 3Q earnings results. AMGN reported a $0.34 EPS beat on another strong quarter of key product growth and cost controls. Management still sees double-digit EPS growth out to 2018.

Analyst Matthew Roden commented, "AMGN reported a $0.34 EPS beat (14% over consensus) on another strong quarter of... More

Amgen (AMGN) Tops Q3 EPS by 35c; Raises Outlook

October 28, 2015 4:03 PM EDT

Amgen (NASDAQ: AMGN) reported Q3 EPS of $2.72, $0.35 better than the analyst estimate of $2.37. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.32 billion.

Amgen sees FY2015 EPS of $9.95-$10.10, versus the consensus of $9.75. Amgen sees FY2015 revenue of $21.4-21.6 billion, versus the consensus of $21.25 billion.

Amgen sees FY2016 EPS of $10.35-$10.75, versus the consensus of $10.73. Amgen sees FY2016 revenue of $21.7-$22.3 billion, versus the consensus of $22.12 billion.

"We delivered record revenues, adjusted earnings and cash flow in the third quarter, while improving our operating margins and... More